BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fatih N, Camberlein E, Island ML, Corlu A, Abgueguen E, Détivaud L, Leroyer P, Brissot P, Loréal O. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl). 2010;88:477-486. [PMID: 20169331 DOI: 10.1007/s00109-009-0588-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Angmo S, Rana S, Yadav K, Sandhir R, Singhal NK. Novel Liposome Eencapsulated Guanosine Di Phosphate based Therapeutic Target against Anemia of Inflammation. Sci Rep 2018;8:17684. [PMID: 30523271 DOI: 10.1038/s41598-018-35992-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov 2017;16:400-23. [PMID: 28154410 DOI: 10.1038/nrd.2016.248] [Cited by in Crossref: 123] [Cited by in F6Publishing: 119] [Article Influence: 24.6] [Reference Citation Analysis]
3 Lainé F, Laviolle B, Bardou-jacquet E, Fatih N, Jezequel C, Collet N, Ropert M, Morcet J, Hamon C, Reymann J, Loréal O. Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo-controlled, randomized, double-blind, cross-over study. Fundam Clin Pharmacol 2017;31:567-73. [DOI: 10.1111/fcp.12288] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
4 Agarwal AK, Yee J. Hepcidin. Advances in Chronic Kidney Disease 2019;26:298-305. [DOI: 10.1053/j.ackd.2019.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
5 Milman NT. A Review of Nutrients and Compounds, Which Promote or Inhibit Intestinal Iron Absorption: Making a Platform for Dietary Measures That Can Reduce Iron Uptake in Patients with Genetic Haemochromatosis. J Nutr Metab 2020;2020:7373498. [PMID: 33005455 DOI: 10.1155/2020/7373498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Sebastiani G, Wilkinson N, Pantopoulos K. Pharmacological Targeting of the Hepcidin/Ferroportin Axis. Front Pharmacol 2016;7:160. [PMID: 27445804 DOI: 10.3389/fphar.2016.00160] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
7 Rana S, Prabhakar N. Iron disorders and hepcidin. Clin Chim Acta 2021;523:454-68. [PMID: 34755647 DOI: 10.1016/j.cca.2021.10.032] [Reference Citation Analysis]
8 Zhang F, Zhao P, Qian Z, Zhong M. Central Nervous System Inflammation Induced by Lipopolysaccharide Up-Regulates Hepatic Hepcidin Expression by Activating the IL-6/JAK2/STAT3 Pathway in Mice. Front Nutr 2021;8:649640. [PMID: 33869267 DOI: 10.3389/fnut.2021.649640] [Reference Citation Analysis]
9 Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011;57:1650-1669. [PMID: 21989113 DOI: 10.1373/clinchem.2009.140053] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 13.9] [Reference Citation Analysis]
10 Gangat N, Wolanskyj AP. Anemia of Chronic Disease. Seminars in Hematology 2013;50:232-8. [DOI: 10.1053/j.seminhematol.2013.06.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
11 Larson DS, Coyne DW. Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease. Kidney Res Clin Pract 2013;32:11-5. [PMID: 26894030 DOI: 10.1016/j.krcp.2013.01.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
12 Bardou-Jacquet E, Ben Ali Z, Beaumont-Epinette MP, Loreal O, Jouanolle AM, Brissot P. Non-HFE hemochromatosis: pathophysiological and diagnostic aspects. Clin Res Hepatol Gastroenterol 2014;38:143-54. [PMID: 24321703 DOI: 10.1016/j.clinre.2013.11.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
13 Zhang SP, Wang Z, Wang LX, Liu SJ. AG490: An inhibitor of hepcidin expression in vivoWorld J Gastroenterol 2011; 17(45): 5032-5034 [PMID: 22174555 DOI: 10.3748/wjg.v17.i45.5032] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
14 Messner DJ, Rhieu BH, Kowdley KV. Iron overload causes oxidative stress and impaired insulin signaling in AML-12 hepatocytes. Dig Dis Sci. 2013;58:1899-1908. [PMID: 23558563 DOI: 10.1007/s10620-013-2648-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
15 Wang YS, Zhang FK. [Advances on diagnosis and treatment of anemia of inflammation]. Zhonghua Xue Ye Xue Za Zhi 2018;39:782-6. [PMID: 30369194 DOI: 10.3760/cma.j.issn.0253-2727.2018.09.017] [Reference Citation Analysis]
16 de Las Cuevas Allende R, Díaz de Entresotos L, Conde Díez S. Anaemia of chronic diseases: Pathophysiology, diagnosis and treatment. Med Clin (Barc) 2021;156:235-42. [PMID: 33358297 DOI: 10.1016/j.medcli.2020.07.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011;2011:538-42. [PMID: 22160086 DOI: 10.1182/asheducation-2011.1.538] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 7.6] [Reference Citation Analysis]
18 Ware BR, Brown GE, Soldatow VY, LeCluyse EL, Khetani SR. Long-Term Engineered Cultures of Primary Mouse Hepatocytes for Strain and Species Comparison Studies During Drug Development. Gene Expr 2019;19:199-214. [PMID: 31340881 DOI: 10.3727/105221619X15638857793317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Schmid H, Jelkmann W. Investigational therapies for renal disease-induced anemia. Expert Opinion on Investigational Drugs 2016;25:901-16. [DOI: 10.1080/13543784.2016.1182981] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
20 Kato A. Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio–renal anemia syndrome. Future Cardiology 2010;6:769-71. [DOI: 10.2217/fca.10.97] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bartnikas TB, Fleming MD. A tincture of hepcidin cures all: the potential for hepcidin therapeutics. J Clin Invest 2010;120:4187-90. [PMID: 21099105 DOI: 10.1172/JCI45043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Byrne SL, Buckett PD, Kim J, Luo F, Sanford J, Chen J, Enns C, Wessling-Resnick M. Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo. PLoS One 2013;8:e70199. [PMID: 23894616 DOI: 10.1371/journal.pone.0070199] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
23 Blanchette NL, Manz DH, Torti FM, Torti SV. Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev Hematol 2016;9:169-86. [PMID: 26669208 DOI: 10.1586/17474086.2016.1124757] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
24 Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol 2014;5:86. [PMID: 24808863 DOI: 10.3389/fphar.2014.00086] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 9.5] [Reference Citation Analysis]
25 Ginzburg YZ. Hepcidin-ferroportin axis in health and disease. Vitam Horm 2019;110:17-45. [PMID: 30798811 DOI: 10.1016/bs.vh.2019.01.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
26 Reichert CO, da Cunha J, Levy D, Maselli LMF, Bydlowski SP, Spada C. Hepcidin: Homeostasis and Diseases Related to Iron Metabolism. Acta Haematol 2017;137:220-36. [DOI: 10.1159/000471838] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
27 Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment. Nutrients 2021;13:3732. [PMID: 34835988 DOI: 10.3390/nu13113732] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney International 2011;80:240-4. [DOI: 10.1038/ki.2011.141] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
29 Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest 2013;123:2337-43. [PMID: 23722909 DOI: 10.1172/JCI67225] [Cited by in Crossref: 123] [Cited by in F6Publishing: 56] [Article Influence: 13.7] [Reference Citation Analysis]
30 Vyoral D, Jiri Petrak. Therapeutic potential of hepcidin − the master regulator of iron metabolism. Pharmacological Research 2017;115:242-54. [DOI: 10.1016/j.phrs.2016.11.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
31 Samba-Mondonga M, Constante M, Fragoso G, Calvé A, Santos MM. Curcumin induces mild anemia in a DSS-induced colitis mouse model maintained on an iron-sufficient diet. PLoS One 2019;14:e0208677. [PMID: 31026259 DOI: 10.1371/journal.pone.0208677] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
32 Katsarou A, Pantopoulos K. Hepcidin Therapeutics. Pharmaceuticals (Basel) 2018;11:E127. [PMID: 30469435 DOI: 10.3390/ph11040127] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
33 Czaya B, Faul C. The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia. Int J Mol Sci 2019;20:E4195. [PMID: 31461904 DOI: 10.3390/ijms20174195] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
34 Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87:392-400. [PMID: 22290531 DOI: 10.1002/ajh.23110] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 11.4] [Reference Citation Analysis]
35 Langer AL, Ginzburg YZ. Role of hepcidin-ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammation. Hemodial Int 2017;21 Suppl 1:S37-46. [PMID: 28328181 DOI: 10.1111/hdi.12543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
36 Madeddu C, Neri M, Sanna E, Oppi S, Macciò A. Experimental Drugs for Chemotherapy- and Cancer-Related Anemia. J Exp Pharmacol 2021;13:593-611. [PMID: 34194245 DOI: 10.2147/JEP.S262349] [Reference Citation Analysis]
37 Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based Therapies. Front Immunol 2017;8:339. [PMID: 28424688 DOI: 10.3389/fimmu.2017.00339] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 18.8] [Reference Citation Analysis]
38 Murawska N, Fabisiak A, Fichna J. Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment. Inflamm Bowel Dis. 2016;22:1198-1208. [PMID: 26818422 DOI: 10.1097/mib.0000000000000648] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
39 Rochette L, Gudjoncik A, Guenancia C, Zeller M, Cottin Y, Vergely C. The iron-regulatory hormone hepcidin: A possible therapeutic target? Pharmacology & Therapeutics 2015;146:35-52. [DOI: 10.1016/j.pharmthera.2014.09.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]